Related references
Note: Only part of the references are listed.Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling
Ian M. Silverman et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2022)
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
Funda Meric-Bernstam et al.
CANCER DISCOVERY (2022)
Accurate and efficient detection of gene fusions from RNA sequencing data
Sebastian Uhrig et al.
GENOME RESEARCH (2021)
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions
Elspeth A. Bruford et al.
LEUKEMIA (2021)
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Milind Javle et al.
Lancet Gastroenterology & Hepatology (2021)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma
Fangda Li et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays
Martina Kirchner et al.
GENES CHROMOSOMES & CANCER (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch et al.
JCO GLOBAL ONCOLOGY (2020)
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
Alessandro Rizzo et al.
CANCER CONTROL (2020)
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Timothy Kendall et al.
LIVER INTERNATIONAL (2019)
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma
Masayuki Akita et al.
HPB (2019)
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
Martina Kirchner et al.
CANCERS (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples
Kurtis D. Davies et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations
Leandro H. Gallo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
Jau-Yu Liau et al.
MODERN PATHOLOGY (2014)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
Inhibition of Basal FGF Receptor Signaling by Dimeric Grb2
Chi-Chuan Lin et al.
CELL (2012)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Survival analysis of cholangiocarcinoma: A 10-year experience in Malaysia
Ahmad Ramzi Yusoff et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Integrative genomics viewer
James T. Robinson et al.
NATURE BIOTECHNOLOGY (2011)
Direct binding of Grb2 SH3 domain to FGFR2 regulates SHP2 function
Zamal Ahmed et al.
CELLULAR SIGNALLING (2010)
Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform
Jiyoung Y. Cha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Differential signal transduction of alternatively spliced FGFR2 variants expressed epithelial in human mammary cells
Allison B. Moffa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
The human genome browser at UCSC
WJ Kent et al.
GENOME RESEARCH (2002)
Share Paper
